We will likely have a permanent and large SP gain on MHRA approval and that makes NWBO a buy at this SP. In my opinion, we are not staying at less than 60 cents upon approval.
Every investor must to decide on their own but for me, if I am willing to let it all ride through that binary decision then I am willing to buy more (though not by taking on debt) at these fire sale prices.
I did not want or ask for this extended wait but if we must endure it and the continuing dilution at this price level, averaging down is at least a nice compensation especially since we’re finally on the clock over at MHRA with limited room for shenanigans.
That said “Don’t front run the MHRA” is likely to seamlessly transition to “Don’t front run the FDA.”
If that does happen, shareholders still likely make a handsome profit on shares bought down here but some of the wilder price projections will be out of the question.
Either way, 2024 is the year we finally get a permanent and positive SP change. Once these prices are gone, they will (finally) be gone.
News 
Market Data 
Discover 
AI
